



## 2018 Annual Congress of the European Academy of Allergy and Clinical Immunology

# Innovative Solutions for Allergy – EAACI Welcomes the World of Allergy at its Annual Congress in Munich

Munich, Germany, 26 May 2018 – EAACI Congress 2018 Embargo policy lifted: 26 May 2018 – 9:00

#### Allergy a global burden - solutions on the horizon.

Allergy is a disease which is affecting almost a quarter of the population in developed countries, it is common, and increasing, across all age groups. This epidemic continues to have a growing impact on healthcare budgets worldwide, with the total spend on asthma alone in Europe estimated at €72.2 billion per year<sup>1</sup>. The annual congress of the European Academy of Allergy and Clinical Immunology (EAACI) is the largest meeting worldwide of its kind and will take place in Munich this year with the main focus being on innovative solutions for the allergy epidemic. Experts from multiple disciplines are coming together to present major advancements as well as novel challenges. Expertise come in different flavours with a wide range of specialists taking part; from patient organisations to basic scientists, along with clinicians and allied health care professionals, all of whom will be discussing and presenting issues on allergies from different perspectives. This will be done in part via the more than 2000 scientific abstracts submitted and presented by the scientists. In addition, the congress is a breeding forum for a growing number of junior scientists and physicians that are actively working in the EAACI society, as members of the EAACI Junior Member Assembly, to deliver progress and innovations for allergies. Whilst positive pharmaceutic developments are exciting, critical analysis is also given to key issues. EAACI Pro & Con sessions provide the platform for such discussions. Additional hot topics also include the Diesel gate affair, as pollution is one of the factors that make allergies worse. However, the more than 450 invited speakers and an expected 8000 participants from more than 80 countries are also interested in environmental factors that prevent allergies in the first place, or therapies that block the development of rhinitis into asthma. It is the great variety of topics and the contrast of disease developments, which makes the EAACI Congress not only the biggest of its kind, but also the most interesting, with the academy and organisers continuously introduce novel and interactive formats. This year's new comers include patent innovation sessions and for the first time the meeting is also hosting a TV channel, EAACI TV, which broadcasts select content via the internet. There will also be certain live-streamed sessions open to view on www.eaaci.org.

#### **EAACI Congress 2018 in Munich.**

The scientific programme of the EAACI Congress 2018 will present the best in science with educational sessions from distinguished researchers from across the globe. An expected attendance of 8000 participants from more than 80 countries, including more than 450 invited speakers, will address major advances and novel challenges in the field. Covering key topics on allergic diseases and asthma the EAACI Congress provides a multidisciplinary forum for allergists, pulmonologists, ENTs, dermatologists, internists, pediatricians, gastroenterologists, clinical immunologists and primary care physicians, allied health professionals and patients organisation representatives.





### **About EAACI**

The European Academy of Allergy and Clinical Immunology (EAACI) is a non-profit organisation, active in the fields of allergic and immunologic diseases such as asthma, rhinitis, eczema, occupational allergy, food and drug allergy, and anaphylaxis. EAACI was founded in 1956 in Florence, Italy and has become the largest medical association in Europe in the field of allergy and clinical immunology. It includes over 10'000 members from 122 countries, as well as over 60 national and international member societies.

Over the past 62 years, EAACI has dedicated its resources to improving the health of people affected by allergic diseases and asthma. With experience and knowledge in allergy science, EAACI is the primary source of expertise in Europe and beyond for all aspects of allergic diseases and asthma.

#### **Contact**

EAACI Headquarters
Hagenholzstrasse 111, 3rd Floor
8050 Zurich
CH – Switzerland
Tel: +41 79 892 91 39
communications@eaaci.org
www.eaaci.org

 ${\tt iSelroos\,O,\,et\,al.\,(2015,September)}, \textit{National\,and\,regional\,asthma\,programmes\,in\,Europe}, \textit{European}\,\textit{Respiratory}\,\textit{Review\,2015}, 24 (137): 474-483, \textit{retrieved\,from\,https://www.ncbi.nlm.nih.gov/pubmed/26324809}$